Last Price
38.19
Today's Change
+0.05 (0.13%)
Day's Change
37.81 - 38.19
Trading Volume
3,518
Market Cap
1 Billion
Shares Outstanding
26 Million
Avg Volume
13,770
Avg Price (50 Days)
35.96
Avg Price (200 Days)
24.32
PE Ratio
-20.98
EPS
-1.82
Earnings Announcement
13-Aug-2024
Previous Close
38.14
Open
38.14
Day's Range
37.91 - 38.19
Year Range
15.25 - 41.9
Trading Volume
3,518
1 Day Change
0.13%
5 Day Change
-1.32%
1 Month Change
-0.91%
3 Month Change
95.85%
6 Month Change
68.76%
Ytd Change
52.76%
1 Year Change
114.55%
3 Year Change
31.10%
5 Year Change
94.85%
10 Year Change
94.85%
Max Change
94.85%
No result.
Sector: Healthcare - Healthcare
Industry: Biotechnology
Description:
Calliditas Therapeutics AB (publ), a clinical-stage biopharmaceutical company, focused on identifying, developing, and commercializing pharmaceuticals products for treatments in orphan indications with initial focus on renal and hepatic diseases. It offers Nefecon, an oral formulation of budesonide that is an immunosuppressant for the treatment of the autoimmune renal disease immunoglobulin A nephropathy. The company's lead product candidate is Setanaxib, a NOX inhibitor that is in Phase 2b/3 clinical trial for the treatment of primary biliary cholangitis; and in Phase 2 clinical trial for the treatment of squamous cell carcinoma of the head and neck cancer and idiopathic pulmonary fibrosis, as well as for type 1 diabetic kidney disease. It also develops Budenofalk 3 mg oral capsules for the treatment of autoimmune hepatitis. The company was incorporated in 2004 and is headquartered in Stockholm, Sweden.